微生物組療法市場：依產品類型、給藥途徑、醫療機構和地區分類

據估計，微生物組療法市場在2026年的價值為5,740萬美元，預計到2033年將達到3.106億美元。預計從2026年到2033年，該市場將以27.3%的複合年成長率成長。

全球微生物組療法市場是醫療保健領域的創新方向，它利用體內微生物之間的生物相互作用，為多種疾病提供保護和治療。其實現方式是透過各種療法，包括生物製藥產品、微生物組衍生藥物和人工建構的微生物群落，來重新調節微生物組群落的平衡。隨著越來越多的證據顯示微生物組失調與疾病發展密切相關，人們對這一領域的關注度也日益成長。

次世代定序、計算生物學和合成生物學技術的進步，使得個人化微生物組療法的開發成為可能，這與精準醫療的當前發展趨勢相符。這促使一些大型製藥企業大力投資微生物組產業，因為它有望解決傳統方法無法應對的健康問題。

市場動態

由於發炎性腸道疾病、克隆氏症和潰瘍性大腸炎等慢性疾病的盛行率不斷上升，全球以微生物組為基礎的療法市場正蓬勃發展。這些疾病與微生物組失衡密切相關，因此亟需創新療法進行治療。此外，醫療專業人員和患者對腸道微生物組在整體健康中作用的認知不斷提高，也進一步推動了對新型微生物組療法的需求。基因組學、生物資訊學和合成生物學的科學進步使療法研發變得更加便捷。然而，監管標準和漫長的臨床檢驗流程、高成本的研發成本以及微生物組的多樣性，仍為產品研發帶來挑戰。

然而，隨著微生物組的應用範圍不斷擴大，涵蓋胃腸道疾病、腫瘤、代謝性疾病、神經系統疾病和皮膚病等領域，市場蘊藏著許多機會。基於個別微生物組譜的個人化療法的引入，將有助於變革治療技術，並契合精準醫療的當前趨勢。此外，生物技術公司與學術機構之間的合作研究日益活躍，推動了創新和研究成果的商業化。

本次調查的主要特點

• 本研究揭示了各個細分市場的潛在商機，並為該市場說明了一個具有吸引力的投資提案矩陣。
• 此外，本研究還深入分析了市場促進因素、限制因素、機會、新產品發布和核准、市場趨勢、區域展望以及主要參與者採取的競爭策略。
• 本研究根據以下參數對全球微生物組療法市場的主要參與者進行了分析：公司概況、產品系列、主要亮點、財務表現和策略。
• 透過利用本報告中的見解，企業行銷負責人和經營團隊將能夠就未來的產品發布、產品升級、市場擴張和行銷策略做出明智的決策。
• 這份全球微生物組療法市場報告面向產業內的各種相關人員，包括投資者、供應商、產品製造商、經銷商、新參與企業和金融分析師。
• 透過對全球微生物組療法市場進行分析時所使用的各種策略矩陣，相關人員將能夠更輕鬆地做出決策。

目錄

第1章：研究目標與前提條件

• 研究目標
• 前提
• 簡稱

第2章 市場範圍

• 報告摘要
  • 市場定義和範圍
• 執行摘要

第3章：市場動態、監管與趨勢分析

• 市場動態
• 影響分析
• 主要亮點
• 法規環境
• 產品上市及核准
• PEST分析
• 波特的分析
• 市場機遇
• 法規環境
• 主要進展
• 產業趨勢

第4章 全球微生物組療法市場：依產品類型分類，2021-2033年

• Rebyota
• Vowst
• 生物米克特拉
• 處於開發後期階段的產品

第5章 全球微生物組療法市場：依給藥途徑分類，2021-2033年

• 口服
• 直腸

第6章 全球微生物組療法市場：依醫療保健機構分類，2021-2033年

• 醫院
• 專科藥房
• 診所

第7章 全球微生物組療法市場：依地區分類，2021-2033年

• 北美洲
  • 美國
  • 加拿大
• 拉丁美洲
  • 巴西
  • 阿根廷
  • 墨西哥
  • 其他拉丁美洲
• 歐洲
  • 德國
  • 英國
  • 西班牙
  • 法國
  • 義大利
  • 俄羅斯
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國
  • ASEAN
  • 亞太其他地區
• 中東
  • 海灣合作理事會國家
  • 以色列
  • 其他中東國家
• 非洲
  • 南非
  • 北非
  • 中非

第8章 競爭情勢

• Seres Therapeutics, Inc.
• Vedanta Biosciences, Inc.
• Finch Therapeutics Group, Inc.
• Enterome SA
• 4D Pharma plc
• Locus Biosciences, Inc.
• Rebiotix Inc.
• Second Genome Therapeutics
• Microbiotica Ltd.
• Synlogic, Inc.

第9章 分析師建議

• 機會
• 分析師意見
• 連貫的機會地圖

第10章 參考文獻與調查方法

• 參考
• 調查方法
• 關於本公司

Microbiome Therapeutics Market is estimated to be valued at USD 57.4 Mn in 2026 and is expected to reach USD 310.6 Mn by 2033, growing at a compound annual growth rate (CAGR) of 27.3% from 2026 to 2033.

The global microbiome therapeutics market is an innovative field in the healthcare sector that utilizes the biological interaction between the microorganisms in the body to offer protection from various diseases and treatment. This is achieved through rebalancing of the microbiome community by use of different forms of therapeutics, including live biotherapeutics products, drugs made from the microbiome, and engineered microbial communities. The evidence that has been emerging showing the link between dysbiosis in the microbiome community and disease development has contributed to increased interests in this area.

The advancements in next-generation sequencing, computational, and synthetic biology technology have made it possible to produce custom-made microbiome therapies that align well with the current trend in precision medicine. This has made some of the big pharma companies invest heavily in the microbiome industry due to its potential in solving health issues that can only be addressed by conventional methods.

Market Dynamics

The global microbiome therapeutics market has gained traction due to the rise in prevalence of chronic ailments including inflammatory bowel diseases, Crohn's disease, and ulcerative colitis. Since these ailments are highly dependent on microbiome imbalance, they require innovative therapies for treatment. Rising awareness among the medical practitioners and patients about the role played by gut microbiomes in their general well-being has further spurred demand for new microbiome-based products. Scientific breakthroughs in genomics, bioinformatics, and synthetic biology have made it easier to develop therapeutics successfully. Nevertheless, various challenges remain as regulatory norms and lengthy clinical validation processes make it tough to develop products along with high costs associated with the process of creation and diverse nature of microbiome.

Nevertheless, there are multiple chances offered by the market with the development of applications of microbiomes from gastrointestinal problems to oncological, metabolic, neurology, and dermatology issues. The introduction of personalized therapy according to an individual microbiome profile contributes to changes in treatment techniques and corresponds to the current tendencies of precision medicine. In addition, more and more joint efforts of biotech companies and academic institutions are leading to increased innovations and research commercialization.

Key Features of the Study

• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global microbiome therapeutics market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include Seres Therapeutics, Inc., Vedanta Biosciences, Inc., Finch Therapeutics Group, Inc., Enterome SA, 4D Pharma plc, Locus Biosciences, Inc., Rebiotix Inc., Second Genome Therapeutics, Microbiotica Ltd., and Synlogic, Inc.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global microbiome therapeutics market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global microbiome therapeutics market

Market Segmentation

• Product Type Insights (Revenue, USD Mn, 2021 - 2033)
  • Rebyota
  • Vowst
  • Biomictra
  • Late Phase Products
• Route of Administration Insights (Revenue, USD Mn, 2021 - 2033)
  • Oral
  • Rectal
• Care Setting Insights (Revenue, USD Mn, 2021 - 2033)
  • Hospitals
  • Specialty Pharmacies
  • Physicians Clinics
• Regional Insights (Revenue, USD Mn, 2021 - 2033)
  • North America
  • U.S.
  • Canada
  • Latin America
  • Brazil
  • Argentina
  • Mexico
  • Rest of Latin America
  • Europe
  • Germany
  • U.K.
  • Spain
  • France
  • Italy
  • Russia
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
  • Middle East
  • GCC Countries
  • Israel
  • Rest of Middle East
  • Africa
  • South Africa
  • North Africa
  • Central Africa
• Key Players Insights
  • Seres Therapeutics, Inc.
  • Vedanta Biosciences, Inc.
  • Finch Therapeutics Group, Inc.
  • Enterome SA
  • 4D Pharma plc
  • Locus Biosciences, Inc.
  • Rebiotix Inc.
  • Second Genome Therapeutics
  • Microbiotica Ltd.
  • Synlogic, Inc.

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Global Microbiome Therapeutics Market, By Product Type
  • Global Microbiome Therapeutics Market, By Route of Administration
  • Global Microbiome Therapeutics Market, By Care Setting
  • Global Microbiome Therapeutics Market, By Region

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
• Impact Analysis
• Key Highlights
• Regulatory Scenario
• Product Launches/Approvals
• PEST Analysis
• PORTER's Analysis
• Market Opportunities
• Regulatory Scenario
• Key Developments
• Industry Trends

4. Global Microbiome Therapeutics Market, By Product Type, 2021-2033, (USD Mn)

• Introduction
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2022 - 2033
  • Segment Trends
• Rebyota
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
• Vowst
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
• Biomictra
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
• Late Phase Products
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)

5. Global Microbiome Therapeutics Market, By Route of Administration, 2021-2033, (USD Mn)

• Introduction
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2022 - 2033
  • Segment Trends
• Oral
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
• Rectal
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)

6. Global Microbiome Therapeutics Market, By Care Setting, 2021-2033, (USD Mn)

• Introduction
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2022 - 2033
  • Segment Trends
• Hospitals
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
• Specialty Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
• Physicians Clinics
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)

7. Global Microbiome Therapeutics Market, By Region, 2021 - 2033, Value (USD Mn)

• Introduction
  • Market Share (%) Analysis, 2026, 2029 & 2033, Value (USD Mn)
  • Market Y-o-Y Growth Analysis (%), 2022 - 2033, Value (USD Mn)
  • Regional Trends
• North America
  • Introduction
  • Market Size and Forecast, By Product Type, 2021 - 2033, Value (USD Mn)
  • Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Mn)
  • Market Size and Forecast, By Care Setting, 2021 - 2033, Value (USD Mn)
  • Market Size and Forecast, By Country, 2021 - 2033, Value (USD Mn)
    • U.S.
    • Canada
• Latin America
  • Introduction
  • Market Size and Forecast, By Product Type, 2021 - 2033, Value (USD Mn)
  • Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Mn)
  • Market Size and Forecast, By Care Setting, 2021 - 2033, Value (USD Mn)
  • Market Size and Forecast, By Country, 2021 - 2033, Value (USD Mn)
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
• Europe
  • Introduction
  • Market Size and Forecast, By Product Type, 2021 - 2033, Value (USD Mn)
  • Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Mn)
  • Market Size and Forecast, By Care Setting, 2021 - 2033, Value (USD Mn)
  • Market Size and Forecast, By Country, 2021 - 2033, Value (USD Mn)
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, By Product Type, 2021 - 2033, Value (USD Mn)
  • Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Mn)
  • Market Size and Forecast, By Care Setting, 2021 - 2033, Value (USD Mn)
  • Market Size and Forecast, By Country, 2021 - 2033, Value (USD Mn)
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
• Middle East
  • Introduction
  • Market Size and Forecast, By Product Type, 2021 - 2033, Value (USD Mn)
  • Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Mn)
  • Market Size and Forecast, By Care Setting, 2021 - 2033, Value (USD Mn)
  • Market Size and Forecast, By Country, 2021 - 2033, Value (USD Mn)
    • GCC Countries
    • Israel
    • Rest of Middle East
• Africa
  • Introduction
  • Market Size and Forecast, By Product Type, 2021 - 2033, Value (USD Mn)
  • Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Mn)
  • Market Size and Forecast, By Care Setting, 2021 - 2033, Value (USD Mn)
  • Market Size and Forecast, By Country/Region, 2021 - 2033, Value (USD Mn)
    • South Africa
    • North Africa
    • Central Africa

8. Competitive Landscape

• Seres Therapeutics, Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Vedanta Biosciences, Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Finch Therapeutics Group, Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Enterome SA
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• 4D Pharma plc
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Locus Biosciences, Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Rebiotix Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Second Genome Therapeutics
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Microbiotica Ltd.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Synlogic, Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies

9. Analyst Recommendations

• Wheel of Fortune
• Analyst View
• Coherent Opportunity Map

10. References and Research Methodology

• References
• Research Methodology
• About us